| Cat. No. | Species | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|
| PGF-H52G3 | Human | Human PLGF / PGF (19-149) Protein, GST Tag |  |
||
| PGF-H5255 | Human | Human PLGF / PGF (19-221) Protein, Fc Tag (MALS verified) |  |
|
|
| PGF-H5256 | Human | Human PLGF / PGF (19-149) Protein, Fc Tag (MALS verified) |  |
|
|
| PGF-H52H5 | Human | Human PLGF / PGF (19-149) Protein, His Tag (MALS verified) |  |
|
|
| PGF-M52H0 | Mouse | Mouse PLGF / PGF Protein, His Tag |  |
|
|
| PGF-R52H0 | Rhesus macaque | Rhesus macaque PLGF / PGF Protein, His Tag |  |
|
|
| PGF-H5229 | Human | Human PLGF / PGF Protein, His Tag |  |
|
|
Immobilized Human VEGF R1, His Tag (Cat. No. VE1-H5220) at 2 μg/mL (100 μL/well) can bind Human PLGF (19-149), Fc Tag (Cat. No. PGF-H5256) with a linear range of 0.6-5 ng/mL (QC tested).
The purity of Human PLGF (19-221), Fc Tag (Cat. No. PGF-H5255) is more than 85% and the molecular weight of this protein is around 115-130 kDa verified by SEC-MALS.
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Ziv-aflibercept | BAY-865321; AVE-0005 | Approved | Regeneron Pharmaceuticals Inc, Sanofi | Zaltrap | Japan | Colorectal Neoplasms | Sanofi | 2012-08-03 | Ovarian Neoplasms; Solid tumours; Ascites; Lung Diseases; Prostatic Neoplasms; Colorectal Neoplasms; Lung Neoplasms; Lymphoma; Neoplasm Metastasis | Details |
| Aflibercept | BAT-86-5321; BAY-865321 | Approved | Regeneron Pharmaceuticals Inc, Bayer Ag | Eylea | Mainland China | Macular Degeneration; Macular Edema | Bayer Australia Ltd | 2011-11-18 | Diabetes Complications; Neoplasm Metastasis; Retinopathy of Prematurity; Retinal Vein Occlusion; Macular Degeneration; Diabetic Retinopathy; Diabetes Mellitus; Retinal Degeneration; Colorectal Neoplasms; Diabetes Mellitus, Type 1; Prostatic Neoplasms; Wet Macular Degeneration; Diabetic macular oedema; Myopia, Degenerative; Retinal Diseases; Glaucoma, Neovascular; Diabetes Mellitus, Type 2; Macular Edema | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| Aflibercept biosimilar (Sam Chun Dang Pharm) | SCD-411 | Phase 3 Clinical | Sam Chun Dang Pharm Co Ltd | Macular Degeneration | Details |
| Aflibercept Biosimilar (Clover Biopharmaceuticals) | SCB-420 | Phase 1 Clinical | Sichuan Sanyecao Bio-Pharmaceutical Co Ltd | Diabetic macular oedema; Macular Degeneration | Details |
| Aflibercept biosimilar (Momenta/Mylan) | M-710; MYL-1701P | Phase 3 Clinical | Mylan, Momenta | Diabetic macular oedema | Details |
| Aflibercept biosimilar (CinnaGen)(阿柏西普生物类似药（CinnaGen）) | Phase 3 Clinical | Cinnagen | Macular Degeneration | Details | |
| Aflibercept Biosimilar (Boan Biopharma/Luye Pharma） | LY-09004; BA-9101; OT-702 | Phase 3 Clinical | Shandong Boan Biotechnology Co Ltd, Luye Pharma Group Ltd | Wet Macular Degeneration; Macular Degeneration | Details |
| Ziv-aflibercept biosimiliar (Boan Biopharma) | LY-01012; BA-1103 | Phase 1 Clinical | Shandong Boan Biotechnology Co Ltd | Colorectal Neoplasms | Details |
| CT-P42 | CT-P42 | Phase 3 Clinical | Celltrion | Diabetic macular oedema | Details |
| Aflibercept/Nesvacumab | REGN 910-3 | Phase 2 Clinical | Regeneron Pharmaceuticals Inc | Diabetic macular oedema; Macular Degeneration | Details |
| FYB-203 | FYB-203 | Phase 3 Clinical | Formycon | Macular Degeneration | Details |
| Anti-placental growth factor monoclonal antibody | αPlGF; R-7334; TB-403; RG-7334; THR-317; RO-5323441 | Phase 2 Clinical | Thrombogenics, Bioinvent International | Retinal Telangiectasis; Medulloblastoma; Solid tumours; Ovarian Neoplasms; Macular Edema; Glioblastoma; Colorectal Neoplasms; Carcinoma, Hepatocellular; Diabetic Retinopathy; Macular Degeneration; Diabetes Mellitus | Details |
| Aflibercept biosimilar (Qilu Pharmaceutical) | QL-1207 | Phase 3 Clinical | Qilu Pharmaceutical Co Ltd | Diabetic macular oedema; Macular Degeneration | Details |
| Aflibercept biosimilar (Mabwell) | 9-MW-0813; 9MW-0813; 9MW0813; 9-MW0813 | Phase 3 Clinical | Mabwell (Shanghai) Bioscience Co Ltd | Diabetic macular oedema | Details |
| Aflibercept Biosimilar(Alvotech Swiss) | AVT-06 | Phase 3 Clinical | Alvotech Swiss Ag | Macular Degeneration | Details |
| Aflibercept biosimilar (Amgen) | ABP-938 | Phase 2 Clinical | Amgen Inc | Macular Degeneration | Details |
| 4D-150 | 4D-150 | Phase 2 Clinical | 4d Molecular Therapeutics Inc | Diabetic macular oedema; Macular Degeneration; Diabetic Retinopathy | Details |
| Aflibercept biosimilar (Samsung Bioepis) | SB-15 | Phase 3 Clinical | Samsung Bioepis | Macular Degeneration | Details |
This web search service is supported by Google Inc.
A-Z
